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The field of Interstital Lung Disease (ILD) has undergone significant evolution in recent years, with an 
increasing incidence and more complex, ever expanding disease classification. In their most severe 
forms these diseases lead to progressive loss of lung function, respiratory failure and eventually 
death. Despite notable advances, progress has been challenged by a poor understanding of 
pathological mechanisms and patient heterogeneity, including, variable progression. The diagnostic 
pathway is thus being continually refined, with the introduction of tools such as transbronchial cryo 
lung biopsy and a move towards genetically aided, precision medicine. In this chapter, we will focus 
on  how to approach a patient with ILD and the diagnostic process.  
INTRODUCTION  
Interstitial lung disease (ILD) is an umbrella term for over 200 different diseases which display  
considerable variation in terms of clinical course, treatment and prognosis. Broadly speaking they 
can be sub-divided into those with an identifiable cause and those without, the latter being referred 
to as idiopathic interstitial pneumonias (IIPs). Clinical assessment aims to identify a possible cause; 
screening for features of systemic disease (e.g. connective tissue disease, CTD) or environmental 
triggers. Relevant exposures include pneumotoxic drugs, radiation therapy, occupational exposures 
(e.g. asbestosis) or implicated allergens (hypersensitivity pneumonitis, HP).   
 
Distinguishing the various forms of pulmonary fibrosis is critical for determining correct 
management and for predicting prognosis, however, this is often obfuscated by the fact the lung has 
a limited repertoire in response to injury and consequently, a finite number of disease patterns. In 
essence, all ILD is characterised by variable degrees of inflammation and fibrosis, not only between 
diseases, but also among individuals with the same disease (Figure a). In inflammation dominant 
disease the histology is that of organsing pneumonia, or non-specific interestitial pneumonitis 
(NSIP), whilst in fibrosis dominant disease, one would expect to see usual interstitial pneumonitis 
(UIP), characterised by fibroblastic foci and only mild to moderate inflammation. These histological 
patterns are associated with specific radiological features, the recognition of which may abrogate 
the need for a formal biopsy and tissue diagnosis.  
































































IDIOPATHIC PULMONARY FIBROSIS 
IPF is the most common of the IIPs, with an incidence of approximately 6,000 cases per year in the 
UK, affecting mainly older males. Median survival is worse than many cancers at just three years and 
the disease accounts for 5,300 deaths each year in the UK (1). IPF is a growing problem, with an 
annual increase in incidence of 11% between 1991 and 2003, a rise that is only partly explained by 
an ageing population (2).  
 
As already alluded to, distinguishing IPF from other ILD, including other idiopathic forms, is 
important for multiple reasons. IPF does not respond to immunosuppressive therapy, in fact, 
immunomodulation may worsen outcomes (3). By contrast there is evidence, particularly in 
systemic sclerosis associated ILD (4), of benefit from cyclophosphamide and mutliple case reports 
suggest a potential role for rituximab (5) as salvage therapy in CTD-ILD.  In addition, there are now 
two drugs, pirfenidone and nintedanib, approved by NICE for IPF, however, at an annual cost of 
around £26,000 per patient and the potential for significant side effects, accurate disease 
identification is essential. Finally, IPF has a worse prognosis than other ILD, hence a definitive 
diagnosis allows for timely involvement of palliative care physicians and consideration of lung 
transplantation.  
PATHOGENESIS OF IPF 
The pathogenesis of IPF is complex and poorly understood, but involves aberrant wound healing in 
the context of repetitive alveolar injury. This results in abnormal fibroblast proliferation, 
differentiation and activation, which in turn drives expansion of the extracellular matrix with loss of 
normal lung architecture, whilst inflammation plays a less dominant role. This is illustrated 
schematically in Figure b.  
 
GENETICS IN DIAGNOSIS AND MANAGEMENT OF IPF 
Although the initiating events in IPF are poorly understood, the disease is likely to be the result of 
environment exposures in genetically susceptible individuals. Certainly, it is estimated that 
approximately 20% of IIPs have a genetic component and familial cases (referred to as Familial 
Interstitial Pneumonias, FIP) were first described in the 1950s. The majority of these FIPs are 
autosomal dominant with incomplete penetrance, but some may arise de novo. The most commonly 
affected genes are those involved in surfactant processing and telomere biology. At present, routine 
genetic testing is not recommended, however, ILD patients with at least one affected first degree 
































































relative, should be offered the opportunity to enrol in the UK wide 100,000 Genomes Project, 
whereby they undergo whole genome sequencing.  
Genetics also have a proven role in sporadic IPF. Polymorphisms in the promoter for the gene 
encoding the salivary mucin, 5b (MUC5B) and for the Toll-interacting protein (TOLLIP) are both 
associated with an increased risk of developing IPF, although both result in a relatively mild 
phenotype. These genetic variants provide the first possible targets for precision medicine in IPF, 
with a post hoc analysis of the PANTHER data establishing a variable response to N-acetyl cysteine 
depending on the individual’s TOLLIP genotype (6). 
DIAGNOSTIC WORK UP IN INTERSTITIAL LUNG DISEASES   
Initial investigations include blood tests to detect the presence of autoantibodies (Table 1), 
precipitating immunoglobulins against organic antigens and serum ACE. These tests alone rarely 
confirm the diagnosis and there is potential for both false positive (particularly autoantibodies in 
older patients) and false negative (failure to identify an antigen and IgG does not exclude HP) results, 
however, they can be useful in helping direct further diagnostics.  
 
Pulmonary function tests (PFTs) are key in appraising these patients and whilst they rarely refine the 
specific diagnosis in individuals with proven ILD, they inform on disease severity at baseline and 
response to treatment over follow up.  
RADIOLOGICAL WORK UP 
Chest Radiographs 
A Chest x-ray (CXR) is often the first radiological investigation in ILD patients and whilst it is rarely 
sufficient to make a confident diagnosis, X-ray can play a role in establishing disease chronicity and 
progression. 
 
High Resolution Computed Tomography  
High-resolution computed tomography (HRCT) of the thorax has revolutionised the diagnosis and 
classification of ILD and in many cases removes the need for invasive diagnostic procedures, 
however, the quality of the images is dependent on the scanning protocol employed (Table 2).  
 
The ATS/ERS 2011 consensus statement (7) provides criteria for a definite UIP pattern on HRCT 
(Figure c), with the presence of these conferring a sensitivity of approximately 40%, but a specificity 
of 95% for histological UIP. The main discriminating feature for UIP is the presence of 
































































honeycombing, however, typical CT appearances are only present in two thirds of patients and it is 
in the remaining third of cases, that biopsy may have a role.  
BRONCHOSCOPY IN THE ASSESSMENT OF ILD  
Bronchoalveolar Lavage, Endobronchial Ultrasound and Transbronchial Biopsy 
There is much variation in practice surrounding the use of bronch-alveolar lavage (BAL), particularly 
between European centres and North American colleagues, who rarely utilise it. Clearly, there is 
value in excluding infection, which may be a differential diagnosis, however, BAL alone is rarely 
diagnostic, with perhaps one of the difficulties being a lack of consistency in terms of how samples 
are taken and processed. Under optimal circumstances BAL reflects cellular traffic in the alveolar 
space and the cell differential may provide supplemental information to help refine, rather make a 
diagnosis. In particular, an excess of lymphocytes should call into question a presumptive IPF 
diagnosis, with Ohshimo et al. describing a BAL lymphocytosis of >30% in 6 of 74 patients with 
definite UIP features on HRCT. In all six cases, further investigations led to a final diagnosis of chronic 
hypersensitivity pneumonitis (8).  
 
Transbronchial biopsy (TBB) with standard forceps is a minimally invasive technique, but does not 
always provide adequate lung tissue to establish a final diagnosis.  The biopsies are small, subject to 
crush artefact and may not be representative in spatially heterogeneous disease (9,10). It may, 
however, be helpful in the diagnosis of sarcoidosis and organising pneumonia.  
 
Transbronchial Cryo Lung Biopsy 
Transbronchial cryo lung biopsy (TBCLB) was first described in 2008
 
(11). It has since been shown to 
be a safe, minimally invasive and effective diagnostic tool for the histological diagnosis of ILD, with a 
diagnostic yield of up to 74–80% (11–15).  The advantage of TBCLB over TBB lies in the larger 




 (11–20). In addition, the technique avoids 
crush or bleeding artefact, which can distort the tissue architecture (Figure d). The published data on 
TBCLB shows a safety profile that is comparable to TBB, with bleeding post biopsy in around 10% of 
cases, all of which was controlled bronchoscopically.  The mean rate of pneumothorax requiring 
chest drain insertion is around 4%, although there is a wide variation between centres. 
Exacerbations of ILD are rare (0.5%) and only one mortality has been reported (0.2%) (11–20).   
 
Pajares et al conducted a prospective randomised trial comparing TBCLB with TBB and demonstrated 
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in a histological diagnosis in 74.4% of patients versus 34.2% in the TBB group (p<0.001) (14). When 
comparing this technique with surgical lung biopsy there are various potential advantages. General 
anaesthesia is not necessary and the procedure can be performed as a day case with uncomplicated 
cases returning home the same day. Future clinical trials and an increase in real world experence of 
TBCLB is likely to cement it’s use for selected cases, potentially reducing the number of surgial lung 
biopsies performed.  
SURGICAL LUNG BIOPSY  
Surgical lung biopsies (SLB) are the current gold standard for obtaining histological material in the 
diagnosis of clinically and radiologically unclassifiable ILD. SLB is usually performed via the less 
invasive Video-Assisted Thoracoscopic Surgical (VATS) approach. As previously described the 2011 
ATS/ERS consensus statement means about two thirds of IPF cases can be diagnosed on the basis of 
typical clinical and radiological findings of UIP (Figure e), however, indications are that only 7.5%- 
12% of suspected IPF patients undergo SLB in the UK (28). This reflects clinicians’ reluctance to refer 
patients for a procedure associated with a significant mortality and morbidity.  
 
The average hospital stay associated for a VATS biopsy is 2-4 days (23), with mortality rates of 3-4% 
and an overall complication rate of up to 16% (24). Common complications include; persistent air-
leak, exacerbations of underlying ILD due to mechanical stress of single lung ventilation, bleeding 
and delayed wound healing. In addition, 57% of patients report pain at the incision site 6-12 months 
after surgery
 
(25). It is also worth remembering that SLB does not guarantee a definite pathological 
diagnosis, with diagnosis rates ranging from 34% to 100% (23,24)
 
.  
MULTIDISCIPLINARY TEAM  
Taking into consideration the various investigations involved in ILD diagnosis it is clear that no single 
diagnostic test can provide a confident answer. A consensus approach by a Multidisciplinary Team 
(MDT) with expertise in ILD is thus considered the gold standard (Figure f). The MDT integrates all 
available data at several stages of the work-up. This not only improves inter-observer agreement 
and diagnostic confidence, but may also prevent unnecessary surgical biopsies, whilst identifying 
patients in whom a biopsy may effectively contribute to the diagnosis
 
(26). Current NICE guidelines 
recommend that IPF should only be diagnosed by MDT consensus and stipulates a minimum MDT 
composition (27).  
































































NOVEL THERAPIES IN IPF 
There has been a dramatic increase in clinical trial activity in IPF in recent years, with the discovery 
and approval of two new anti-fibrotic drugs, pirfenidone and nintedanib, heralding a new era in the 
disease. While these novel anti-fibrotic agents have been shown to slow the decline in Forced Vital 
Capacity (FVC) they neither halt progression nor reverse existing fibrosis. In part due to considerable 
cost, their use is restricted by NICE to patients fulfilling certain criteria, namely a FVC of 50-80% 
predicted, thereby excluding patients at each extreme of the disease process and those with 
spuriously maintained FVC due to concurrent emphysema. Given these restrictions, as well as the 
limitations of these therapies, the importance of non-pharmacological therapy such as pulmonary 
rehabilitation, plus the enrolment of patients into clinical trials (Figure g) should not be 
underestimated.  
NOVEL BIOMARKERS:  
The need to distinguish the different IIPs has driven the search for novel diagnostic biomarkers. In 
addition, there are marked survival differences even within specific groups such as IPF. Biomarkers 
that can identify these phenotypes are needed for clinical decision-making, but they also have the 
potential to aid cohort enrichment in clinical trials. Previous landmark studies have beautifully 
illustrated this need, with variable rates of decline in placebo arms leading to inconsistent results 
and a delay in drugs being approved (28).  
To date, efforts have focussed on serum biomarkers (29) that are relatively easy to access and novel 
imaging modalities which potentially inform on disease activity within the lung. In particular, 
Positron emission tomography (PET) allows non-invasive measurement of cellular metabolism in 
vivo.  The 18F-Fluorodeoxyglucose (18F-FDG) PET signal is consistently raised in ILD (30) and is both 
stable and reproducible (Figure h).  In a population of over 200 ILD patients, we have shown that 
baseline measures of 18F-FDG up-take on PET are related to patient survival in both IPF and other 
IIPs (paper in preparation). High pulmonary 18F-FDG up-take is associated with poor survival, giving 
additional information to pulmonary function testing (PFT) and thus, could become a valuable part 
of the initial work up in newly diagnosed patients. 
CONCLUSION  
The diagnosis of ILD is a challenging and involved process. It relies on detailed history taking and the 
integration of various investigations and specialities. The relative rarity of these diseases makes 
distinguishing subtypes even more difficult for clinicians with a mixed respiratory case workload and 
































































thus, infrequent exposure to ILD. Having said this, the incidence of ILD is increasing and there is 
potential for specialist centres to become overwhelmed with patients, putting a greater than ever 
emphasis on collaboration with referring centres and a concerted effort to employ a hub and spoke 
model. This has the added advantage of facilitating a more patient focussed approach, minimising 
the need for unnecessary travel and facilitating access to ancillary local services, such as pulmonary 
rehab, oxygen providers and palliative care services.  
Irrespective of expertise, uncertainty is inherent in the diagnosis of these diseases, although 
arguably encountering ILD on a frequent basis allows the physician to become more comfortable 
with these uncertainties, thus embracing the concept of continuous diagnostic review.  The hope 
remains that in time, reliable, non-invasive biomarkers will identify disease subtypes, predict 
prognosis and potentially replace the need for biopsy. Much of the heterogeneity seen in IPF may be 
explained by the existence of endotypes, in other words, mechanistically different disease subtypes, 
which consequently exhibit very different responses to therapy. Future treatments therefore have 
the potential to be greatly influenced by identifying these groups through the use of genetic testing 
and a move towards personalised disease management.  
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Figure a: Schematic classification of Interstitial Lung Diseases according to aetiology. The finding of 
histological UIP in a patient with an IIP leads to the specific diagnosis of Idiopathic Pulmonary Fibrosis (IPF) 
Figure a  
 
 



































































Figure b: The Pathogenesis of IPF. In an initiating phase, there is lung alveolar epithelial damage with loss of 
the normal lung architecture and disruption of the basement membrane across which gas exchange takes 
place. With further epithelial damage and apoptosis, comes up-regulation of epithelial integrins such as αvβ6 
and a phase of fibroproliferative repair dominates driven by high levels of TGFβ. Released in an inactive 
form, this cytokine requires an activation step facilitated by integrins that bind the RGD motif of pro-TGFβ 
and promote its cleavage and activation. Locally activated TGFβ drives the recruitment of fibroblasts and a 
feed-forward cycle of further TGFβ production. Under these conditions, fibroblasts differentiate into 
myofibroblasts that express high levels of integrin αvβ6, are resistant to apoptosis and lay down collagen 
matrix. Once collagen has been laid down in a lung, the architecture of which is already distorted, gas 
exchange is no longer efficient. There is a change in the vasculature of the lung parenchyma with both fall-
out of blood vessels and neo-angiogenesis driven by local production of vascular endothelial and platelet 
derived growth factors (VEGF and PDGF). At this final phase the lung is irreversibly scarred.    
figure b  
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Figure c: Diagnostic criteria for a definite UIP pattern on HRCT:   1. subpleural, basal predominance; (red). 
2.  reticular abnormality (blue).  3.  honeycombing with or without traction bronchiectasis 
(yellow).  4.  absence of features inconsistent with UIP pattern  
Figure c  
 
 



































































Figure d: Comparison between transbronchial cryo lung biopsy on the left and traditional forceps 
transbronchial biopsy on the right performed on the same patient at two different sittings. TBCLB shows 
preserved architecture of parenchymal tissue and a total biopsy area of 46.81 mm2 and mean biopsy area 
of 11.7 mm2. TBBx is characterised by crush and haemorrhagic artefact and a total biopsy area of 14.11 
mm2 and mean biopsy area of 2.8 mm2.  
Figure d  
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Figure e: Diagnostic algorithm for idiopathic pulmonary fibrosis, in part adapted from the ATS/ERS 
consensus statement  
 
Figure e  
 
 



































































Figure f: The role of Specialist MDTs and Specialist Referral Centres in the diagnosis and management of 
 ILD   
Figure f  
 
 



































































Figure g: Schematic ILD treatment algorithm. *No robust evidence for managing exacerbations with 
variation between centres, should be discussed with specialist centre if possible. GOR; Gastro-oesophageal 
reflux. PHT; pulmonary hypertension 
 
Figure g  
 
 



































































Figure h: PET signal superimposed on HRCT scan of a patient with UIP. A region of interest has been drawn 
around the area of highest SUV.  
figure h  
 
 
































































Antibody Associated CTD 
ANA (>1:320) Many 
RF (>60 IU/mL) 
Anti-CCP 
RA, Sjögrens, SLE 
RA 
Anti-centromere Systemic sclerosis 
Anti-nuclear ANA Systemic sclerosis 
Anti Ro (SS-A) SLE, Sjögrens and others 
Anti La (SS-B) SLE, Sjögrens 
Anti-RNP SLE, MCTD 
Anti-dsDNA SLE 
Anti-Smith  SLE 
 
Anti tRNA synthetase  Poly-/dermatomyositis (anti-synthetase 
syndrome) 
Anti-PM-Scl Systemic sclerosis/ myositis overlap 
Anti-Th/To Systemic sclerosis 
Anti-U3 RNP Systemic sclerosis 
ANCA panel Vasculitides 




Table 1: Autoantibodies in Connective Tissue ILDs 
ANA: antinuclear antibody; RF: Rheumatoid Factor; Anti-CCP: anti-cyclic citrullinated peptide antibody 
anti-RNP: anti-Ribonucleoprotein; anti-dsDNA: anti-double stranded DNA; Anti-PM-Scl: anti polymyositis-
scleroderma; ANCA: Anti-neutrophil cytoplasmic antibodies; RA: rheumatoid arthritis; SLE: Systemic lupus 
erythematosus; MCTD: mixed connective-tissue disease 
 
































































Optimal HRCT technique for evaluation of ILD 
 
• Non-Contrast scans obtained on full inspiration without respiratory motion 
•Contiguous or non-contiguous axial scans with thin sections, reconstructed at ≤2 cm 
intervals 
•Reconstructed slice collimation ≤2 mm 
•High resolution reconstruction algorithm 
•Field of view to include lungs only 
•Expiratory scans are helpful to exclude lobular air trapping suggestive of hypersensitivity 
pneumonitis 
•Prone scans if dependent density obscures detail on supine images 
•Optional coronal and sagittal reconstructions if volumetric images are obtained 
 
Table 2: The ATS/ERS consensus statement for the diagnosis of IPF set out criteria for the optimal 
HRCT technique for evaluation of ILD 
1
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